ReviewJournal of the American Heart Association2024
Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options.
Review in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.European journal of medical research · 2025 · on this mapPooled it
- Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.Journal of the American College of Cardiology · 2024Trial
- Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026.Obesity pillars · 2026Review
- Anti-obesity medications in adults with congenital heart disease: a comprehensive review and expert clinical recommendations.European heart journal. Quality of care & clinical outcomes · 2026Review
- NovelBiomedicines · 2026Article
- Understanding atrial failure: from diagnosis to clinical implications.Nature reviews. Cardiology · 2026Review
- Association of testosterone and testosterone replacement therapy with atrial fibrillation: an updated review.Journal of the Endocrine Society · 2026Review
- Understanding the Diseased Atria.Physiology (Bethesda, Md.) · 2026Review
- Epidemiologic shift and future projections of atrial fibrillation and flutter in North Africa and the Middle East region: A comprehensive Global Burden of Disease analysis.Heart rhythm O2 · 2026Article
- The Effect of Weight Loss and Metabolic Interventions on Recurrence After Atrial Fibrillation Ablation.Journal of clinical medicine · 2026Review
- Associations between prediabetes, type 2 diabetes and incident atrial fibrillation in patients with hypertension: Results from the Swedish Primary Care Cardiovascular Database.American journal of preventive cardiology · 2026Article
- Molecular Basis of Adipose-Cardiac Crosstalk in Cardiovascular Diseases: From Mechanisms to Therapeutic Opportunities.Biomolecules · 2026Review
- Rare TruncatingGenes · 2026Article
- Update on Obesity and Its Relationship to Atherosclerotic Cardiovascular Disease and Associated Risk Factors.Journal of clinical medicine · 2026Review
- Trends in Atrial Fibrillation-Related Mortality Among Adults With Obesity in the United States From 1999 to 2024.Obesity science & practice · 2026Article
- Pre-ablation Weight Loss Via Metabolic Bariatric Surgery is Associated with Lower In-hospital Complications in Patients with Atrial Fibrillation/flutter.Obesity surgery · 2026Article
- Increased Arrhythmic Risk in Obesity Is Transduced by Adipose Tissue-Derived Extracellular Vesicles.JACC. Basic to translational science · 2026Article
- Association of cardiovascular-kidney-metabolic burden with recurrence after first ablation in patients with persistent atrial fibrillation.BMC cardiovascular disorders · 2026Article
- Risk factors for multimorbidity of cardiovascular diseases in the prospective Million Women Study.Open heart · 2026Article
- Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. Obesity-driven structural and electrical remodeling contribute to AF via several reported mechanisms, including adiposity, inflammation, fibrosis, oxidative stress, ion channel alterations, and autonomic dysfunction. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration. Weight loss has been shown to reverse these changes and reduce AF risk and recurrence after ablation. However, studies on how obesity affects pharmacologic or interventional AF treatments are limited. In this review, we discuss mechanisms by which obesity mediates AF and treatment outcomes, aiming to provide insight into obesity-drug interactions and guide personalized treatment for this patient subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.